Business Context and Reporting Period
This Form 8-K is a current report filed by Pluristem Therapeutics Inc. (PSTI) on July 2, 2019, regarding events occurring on June 30, 2019. The company is incorporated in Nevada and trades on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on corporate governance and compensation adjustments rather than financial performance data.
Material Changes
On June 30, 2019, the Board of Directors approved a 25% reduction in the following compensation components, effective immediately:
- Annual salary of the Chief Executive Officer, Yaky Yanay.
- Annual compensation of the Executive Chairman, Zami Aberman.
- Annual fees paid to each of the company's directors.
These reductions are temporary and will remain in effect until the earlier of:
- The company's closing market capitalization on the Nasdaq Capital Market reaching $170 million.
- June 30, 2020.
Guidance, Outlook, and Management Commentary
The filing references a press release issued on July 2, 2019, which includes a letter from CEO Yaky Yanay (Exhibit 99.1). The text of the letter is not included in this filing summary. No specific financial guidance, risk factors, or contingencies are detailed within the body of this 8-K.
Key Facts for Investor Verification
- Verify the current market capitalization of Pluristem Therapeutics Inc. to determine the remaining duration of the compensation cuts.
- Review the attached press release (Exhibit 99.1) for the full context of the CEO's letter and any additional strategic commentary.
- Confirm the exact pre-reduction compensation figures for the CEO, Executive Chairman, and directors to calculate the specific dollar amount of savings.